These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9796889)

  • 1. Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alter in vitro oxidizability.
    O'Neal DN; O'Brien RC; Timmins KL; Grieve GD; Lau KP; Nicholson GC; Kotowicz MA; Best JD
    Diabet Med; 1998 Oct; 15(10):870-7. PubMed ID: 9796889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?
    Balogh Z; Seres I; Harangi M; Kovács P; Kakuk G; Paragh G
    Diabetes Metab; 2001 Nov; 27(5 Pt 1):604-10. PubMed ID: 11694861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A.
    Superko HR; Berneis KK; Williams PT; Rizzo M; Wood PD
    Am J Cardiol; 2005 Nov; 96(9):1266-72. PubMed ID: 16253595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia.
    Vigna GB; Donega P; Passaro A; Zanca R; Cattin L; Fonda M; Pauciullo P; Marotta G; Fellin R; Gasparrini S; Piliego T
    Nutr Metab Cardiovasc Dis; 1999 Oct; 9(5):234-43. PubMed ID: 10656170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fish oil supplementation versus gemfibrozil treatment in hyperlipidemic NIDDM. A randomized crossover study.
    Fasching P; Rohac M; Liener K; Schneider B; Nowotny P; Waldhäusl W
    Horm Metab Res; 1996 May; 28(5):230-6. PubMed ID: 8738112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII.
    Bröijersén A; Hamsten A; Silveira A; Fatah K; Goodall AH; Eriksson M; Angelin B; Hjemdahl P
    Thromb Haemost; 1996 Aug; 76(2):171-6. PubMed ID: 8865525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
    Otvos JD; Collins D; Freedman DS; Shalaurova I; Schaefer EJ; McNamara JR; Bloomfield HE; Robins SJ
    Circulation; 2006 Mar; 113(12):1556-63. PubMed ID: 16534013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
    Durrington PN; Tuomilehto J; Hamann A; Kallend D; Smith K
    Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
    Iovine C; Lilli S; Gentile A; Patti L; Di Marino L; Cipriano P; Riccardi G; Rivellese AA
    Eur J Clin Invest; 2006 Aug; 36(8):560-5. PubMed ID: 16893378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
    Superko HR; Garrett BC; King SB; Momary KM; Chronos NA; Wood PD
    Am J Cardiol; 2009 Feb; 103(3):387-92. PubMed ID: 19166694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.
    Udawat H; Goyal RK
    Indian Heart J; 2001; 53(2):172-6. PubMed ID: 11428472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
    Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
    Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD.
    Dogra G; Irish A; Chan D; Watts G
    Am J Kidney Dis; 2007 Jun; 49(6):776-85. PubMed ID: 17533020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease.
    Tonelli M; Collins D; Robins S; Bloomfield H; Curhan GC
    Am J Kidney Dis; 2004 Nov; 44(5):832-9. PubMed ID: 15492949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients.
    Kockx M; de Maat MP; Knipscheer HC; Kastelein JJ; Kluft C; Princen HM; Kooistra T
    Thromb Haemost; 1997 Oct; 78(4):1167-72. PubMed ID: 9364979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased DNA oxidative susceptibility without increased plasma LDL oxidizability in Type II diabetes: effects of alpha-tocopherol supplementation.
    Sampson MJ; Astley S; Richardson T; Willis G; Davies IR; Hughes DA; Southon S
    Clin Sci (Lond); 2001 Sep; 101(3):235-41. PubMed ID: 11524040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dyslipidaemia and coagulation defects of insulin resistance.
    Frohlich J; Steiner G
    Int J Clin Pract Suppl; 2000 Oct; (113):14-22. PubMed ID: 11965826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies of LDL particle size and susceptibility to oxidation and association with glucose metabolism in children after heart transplantation.
    Siirtola A; Antikainen M; Ala-Houhala M; Solakivi T; Jokela H; Lehtimäki T; Holmberg C; Salo MK
    J Heart Lung Transplant; 2004 Apr; 23(4):418-26. PubMed ID: 15063401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.